You can buy Erlocip at the lowest price at Nextgen.ooo online pharmacy. Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is used in the treatment of non-small cell lung cancer, pancreatic cancer and some other types of cancer. Erlotinib reversibly binds to the EGFR tyrosine kinase at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies show that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of the JAK2 tyrosine kinase found in most patients with polycythemia vera (PV) and in a significant proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This discovery suggests the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
 
Erlotinib inhibits intracellular phosphorylation of epidermal growth factor receptor (EGFR)-related tyrosine kinase. The specificity of inhibition for other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.
 
Erlotinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) with tumors harboring epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations in combination with first-line therapy for patients diagnosed with locally advanced, unresectable, or metastatic pancreatic cancer.
The safety and efficacy of erlotinib in patients with NSCLC whose tumors harbor other EGFR mutations have not been established. In addition, its use in combination with platinum-based chemotherapy is not recommended.